Emicizumab biosimilar (Nanjing Zhengda Tianqing)

艾美赛珠单抗生物类似药（南京正大天晴）

Report date: 2023/01/09 13:25:49

First In Class

Base Information

Drug NameEmicizumab biosimilar (Nanjing Zhengda Tianqing)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionAnti-Factor IXaAnti-Factor XBlood coagulation pathway activation

TargetsCoagulation factor XCoagulation factor IX

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesNanjing Zhengda Tianqing Pharmaceutical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Zhengda Tianqing Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A